A proportion of patients who develop regional and distant recurrences of melanoma after a pathologically negative sentinel lymph node (SN) biopsy are reported to have enhanced signals for melanoma-associated messenger ribonucleic acid (mRNA) when sensitive molecular approaches such as reverse transcriptase polymerase chain reaction (RT-PCR) are used to evaluate their SN tissue. The significance of these findings remains controversial, because the cellular source of the augmented signals cannot be known as the nodal tissue is destroyed during preparation for RT-PCR. Nevertheless, it is claimed that the source of the augmented signal is covert metastatic melanoma cells. To determine whether there are histologically occult metastases in SN and whether there are sources of augmentable melanoma-associated mRNA other than melanoma cells, we applied reverse transcriptase in situ polymerase chain reaction (RT in situ PCR) to formalin-fixed paraffin-embedded nodal tissue. This approach amplifies small amounts of melanoma-associated mRNA and permits identification of cells that express that mRNA. Cells containing MART-1 mRNA were detected in 6 of 21 SNs (29%) and 2 of 16 nonsentinel lymph node (NSNs) (13%) that were tumor negative on hematoxylin and eosin and on immunohistochemical assessment for S-100, MART-1, and HMB-45. In patients with microscopic evidence of melanoma in their SN, MART-1 mRNA-positive cells were identified in 2 of 7 NSNs (29%) that were histologically tumor free. MART-1 mRNA-positive cells were also detected in tumor-negative SN sections from 6 of 7 (86%) nodes that had tumor present in areas of the node not represented in the studied sections. Some cells that expressed MART-1 mRNA that was diffusely distributed in the cytoplasm appeared to be melanoma cells, whereas others resembled macrophages. The latter cells expressed augmented mRNA on granules that were intermixed with melanin granules. In other cases, MART-1 mRNA-positive macrophage-like cells contained nuclei and nucleoli more typical of melanoma cells and may represent the macrophage-melanoma hybrids that have been previously reported. Combination of RT in situ PCR for MART-1 mRNA and immunohistochemistry for CD68 revealed that CD68 was colocalized in some cells that expressed MART-1 mRNA. Some lymph nodes that are tumor negative by histology and immunohistochemistry contain cells that express mRNA for MART-1. Some of these cells may be interpreted as "stealth" melanoma cells in which, despite the presence of MART-1 mRNA, there is an absence of immunohistochemically detectable MART-1 protein. Other cells that contain MART-1 mRNA are clearly not melanoma cells or may represent melanoma hybrids. These findings should be taken into account when interpreting and applying the results of RT-PCR analysis of nodal (and other) tissues.
Abstract: A proportion of patients who develop regional and distant recurrences of melanoma after a pathologically negative sentinel lymph node (SN) biopsy are reported to have enhanced signals for melanoma-associated messenger ribonucleic acid (mRNA) when sensitive molecular approaches such as reverse transcriptase polymerase chain reaction (RT-PCR) are used to evaluate their SN tissue. The significance of these findings remains controversial, because the cellular source of the augmented signals cannot be known as the nodal tissue is destroyed during preparation for RT-PCR. Nevertheless, it is claimed that the source of the augmented signal is covert metastatic melanoma cells. To determine whether there are histologically occult metastases in SN and whether there are sources of augmentable melanoma-associated mRNA other than melanoma cells, we applied reverse transcriptase in situ polymerase chain reaction (RT in situ PCR) to formalin-fixed paraffin-embedded nodal tissue. This approach amplifies small amounts of melanoma-associated mRNA and permits identification of cells that express that mRNA. Cells containing MART-1 mRNA were detected in 6 of 21 SNs (29%) and 2 of 16 nonsentinel lymph node (NSNs) (13%) that were tumor negative on hematoxylin and eosin and on immunohistochemical assessment for S-100, MART-1, and HMB-45. In patients with microscopic evidence of melanoma in their SN, MART-1 mRNA-positive cells were identified in 2 of 7 NSNs (29%) that were histologically tumor free. MART-1 mRNA-positive cells were also detected in tumor-negative SN sections from 6 of 7 (86%) nodes that had tumor present in areas of the node not represented in the studied sections. Some cells that expressed MART-1 mRNA that was diffusely distributed in the cytoplasm appeared to be melanoma cells, whereas others resembled macrophages. The latter cells expressed augmented mRNA on granules that were intermixed with melanin granules. In other cases, MART-1 mRNA-positive macrophage-like cells contained nuclei and nucleoli more typical of melanoma cells and may represent the macrophage-melanoma hybrids that have been previously reported. Combination of RT in situ PCR for MART-1 mRNA and immunohistochemistry for CD68 revealed that CD68 was colocalized in some cells that expressed MART-1 mRNA. Some lymph nodes that are tumor negative by histology and immunohistochemistry contain cells that express mRNA for MART-1. Some of these cells may be interpreted as "stealth" melanoma cells in which, despite the presence of MART-1 mRNA, there is an absence of immunohistochemically detectable MART-1 protein. Other cells that contain MART-1 mRNA are clearly not melanoma cells or may represent melanoma hybrids. These findings should be taken into account when interpreting and applying the results of RT-PCR analysis of nodal (and other) tissues. M alignant melanomas have a high potential for metastasis and usually spread first to regional lymph nodes. Lymphatic mapping and sentinel lymph node (SN) biopsy 44 are recently developed procedures that are widely used in the management of melanoma patients. SN evaluation permits accurate staging of patients and determines the need for additional nodal surgery. Patients who have a melanoma-positive SN currently undergo complete dissection of the affected lymph node basin (completion lymphadenectomy), whereas patients with a histologically negative SN receive no additional nodal surgery. Approximately 20% of patients with a primary melanoma Z1 mm in thickness have metastatic tumor in microscopically assessed hematoxylin and eosin (H&E) and immunohistochemistry sections from the SN. 45, 46 Accurate determination of SN tumor status requires evaluation of multiple sections and immunohistochemistry for multiple melanocyte-lineage-associated antigens. 14 However, a portion of patients assessed as having a metastasis-negative SN on the basis of H&E histology and immunohistology subsequently develop regional (and distant) recurrences. Such patients have been claimed to reflect false-negative SN biopsies.
The false-negative rate of SN (the number of falsenegative SNs divided by the sum of the number of positive SNs and false-negative SNs) has been reported to be 11% to 18%. 7, 13, 39, 46, 58 False negativity has been attributed to technical problems associated with the identification of true SNs by nuclear medicine and surgery and to errors in tissue sampling and interpretation during pathologic assessment. 34 Anomalies of tumor biology and variation in the timing and routing of the spread of tumor cells from the primary site to the SN 34,47 may also explain some "false-negative" SNs. Molecular analyses, including reverse transcriptase polymerase chain reaction (RT-PCR), have been reported to detect enhanced signal for melanoma-associated messenger ribonucleic acid (mRNA) that may indicate micrometastases. 3, 5, 22, 27, 45 This has been considered to indicate the presence of truly occult melanoma cells that are difficult to detect microscopically or that are missed by the relatively limited sampling that is used to evaluate SNs in most pathology protocols. It is, however, also possible that the technique may be too sensitive, augmenting signals for mRNA in cells other than melanoma cells and providing results that are thus "false positive." Evaluation of the results of RT-PCR studies is particularly challenging, as the cellular source of the augmented mRNA signals cannot be directly determined in the RT-PCR approach as the tissue is disrupted during the preparative stages of the technique.
The reverse transcriptase in situ polymerase chain reaction (RT in situ PCR) amplifies and visualizes small amounts of specific mRNA and allows identification of the nature of cells that contain amplified mRNA. We have successfully modified the RT in situ PCR approach to detect melanoma-associated genes in melanoma cell lines 26, 40 and formalin-fixed paraffin-embedded tissues. 25, 31 Messenger RNA expression reflecting the presence of melanomaassociated genes can be detected microscopically in lymph nodes containing metastases using this technique. 31 To detect cells expressing MART-1 (melanoma-associated antigen recognized by T-cell 1: MLANA) mRNA, including histologically occult metastatic melanoma cells, we applied the RT in situ PCR to SNs and nonsentinel lymph nodes (NSNs) that were tumor negative by standard histopathologic and immunohistochemical evaluations.
MATERIALS AND METHODS
A total of 51 tissue blocks from lymph nodes (28 SNs, 23 NSNs) from patients with malignant melanoma were retrieved from the surgical pathology archives of University of California, Los Angeles and evaluated with permission from the institutional review board. Patients had been treated by sentinel lymph node biopsy and completion lymphadenectomy if the SN contained metastatic tumor. Pathologic examination of sentinel lymph node biopsy was performed using published criteria. 14 H&E and immunohistochemically stained (S-100 protein, HMB-45, MART-1) slides from all lymph nodes were re-reviewed to confirm the presence or absence of metastases (A.J.C. and D.R.W.). Micro-scopically, melanoma-free SNs (n = 21) and NSNs (n = 16) were further evaluated. Histologically tumornegative NSNs from patients with tumor-positive SNs were also evaluated (n = 7). Tumor-free microscopic sections from tumor-positive SNs were identified and evaluated (n = 7). As a negative control, we examined 5 tumor-free axillary lymph nodes from patients with breast cancer (3 SNs and 2 NSNs).
RT In Situ PCR Pretreatment
Formalin-fixed, paraffin-embedded tissue sections (4-mm thickness) were deparaffinized and hydrated through xylene and a series of graded ethanols. The slide-mounted tissue sections were digested with trypsin (0.2 to 0.4 mg/ mL) in phosphate-buffered saline (PBS) for periods that ranged from 30 to 60 minutes at 371C (Roche Diagnostics, Mannheim, Germany) for optimization, followed by digestion with RNase-free DNase I (EPICENTRE Biotechnologies, Madison, WI) in PBS at 371C overnight.
One-Step RT-PCR
The single-step RT in situ PCR approach was performed using a technique based on descriptions in recent studies. 2, 31, 32, 48 The Gene Amp EZ rTth (recombinant Thermus thermophilus) RNA PCR Kit (Applied Biosystems, Foster City, CA) was used. The oligonucleotide primer sequences (Invitrogen, Carlsbad, CA) for MART-1 mRNA were derived from a previous study. 55 The forward primer 5 0 -CACGGCCACTCTTACACCAC-3 0 and the reverse primer 5 0 -GGAGCATTGGGAACCACAGG-3 0 yielded a product of 254 bp (Table 1) . Each slide was loaded with the following mixture: 15 mL of 5Â EZ rTth buffer, 9 mL of Mn(OAc) 2 , 2.4 mL each of dATP/dCTT/dGTT/dTTP, 3 mL of rTth DNA polymerase (Applied Biosystems), 0.9 mL of digoxigenin-11-dUTP, 2.4 mL of 2% bovine serum albumin, 1.3 mL of RNase inhibitor (Roche), 2.3 mL of each primer, and 30.7 mL of diethylpyrocarbonate-treated water. The slides were covered with HybriWell sealing covers (Research Products International, Mount Prospect, IL) and placed on the Gene Amp In Situ PCR System 1000 thermal cycler (PerkinElmer, Foster City, CA). Complementary DNA syntheses were performed at 601C for 30 minutes. After initial denaturation at 941C for 3 minutes, the complementary DNA was amplified by 30 cycles of annealing at 551C for 1 minute, followed by denaturation at 941C for 30 seconds. After RT-PCR, the slides were washed in 0.1Â saline-sodium citrate with 2% bovine serum albumin at 601C for 15 minutes and rinsed in Tris-buffered saline 3 times for 5 minutes.
Immunodetection of RT-PCR Products
After incubation with an alkaline phosphataseconjugated anti-digoxigenin antibody (Roche; 1:200) for 30 minutes, the RT-PCR product was developed with nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate (NBT/BCIP; Zymed Laboratories, South San Francisco, CA) for up to 15 minutes. After chromogen development, selected slides were stained by eosin.
Controls
Negative controls were prepared by: (1) 
Double Labeling Using RT In Situ PCR for MART-1 mRNA and Immunohistochemistry for CD68
Double staining using RT in situ PCR for MART-1 mRNA and immunohistochemistry for CD68 antigen was performed on 6 representative MART-1 mRNA-positive cases. After the RT in situ PCR products were developed with NBT/BCIP, immunohistochemistry for CD68 was performed. Endogenous peroxidase activity was blocked by exposure to 3% hydrogen peroxide for 30 minutes. Heat-induced epitope retrieval was performed by boiling in citrate buffer, pH 6.0, for 30 minutes. Monoclonal antibody for CD68 (clone: KP-1; Dako, Glostrup, Denmark) was diluted in PBS at 1:20. Sections were incubated overnight with the primary antibody at 41C. The subsequent development of antibody-bridge labeling was carried out by the streptavidin-biotin-peroxidase method using a biotinylated anti-mouse antibody (Vector Laboratories, Burlingame, CA) and streptavidin horseradish peroxidase (Zymed). The sections were then reacted with aminoethyl carbazole chromogen (Zymed).
RESULTS
Cells containing MART-1 mRNA were detected in 6 of 21 SNs (29%) and 2 of 16 NSNs (13%) that were tumor negative on examination of H&E-stained and immunohistochemistry-stained slides. In cases with a positive SN, MART-1 mRNA-positive cells were found in 2 of 7 NSNs (29%) that were histologically negative. MART-1 mRNA-positive cells were also detected in microscopically tumor-free areas of 6 of 7 (86%) tumorpositive SNs (Table 2) .
Scattered, single isolated cells in the nodal parenchyma that contained diffuse cytoplasmic MART-1 mRNA appeared to be (stealth) melanoma cells. That is, melanoma cells that, despite containing MART-1 mRNA, did not show immunohistochemically detectable MART-1 protein (Figs. 1A-C). With knowledge of the location of RT in situ PCR-positive cells, review of the original H&E-stained slides allowed identification of melanoma cells in the areas of the node remote from the RT in situ PCR-positive cells (Figs. 1D, E) . On the basis of size, nuclear characteristics, and scattered melanin, these cells were consistent with melanoma cells. Some MART-1 mRNA-positive cells contained microdispersed melanin granules, a pattern that is typical of melanogenic cells but lacked a nucleus that would have permitted determination of their malignant or benign status by H&E (Fig. 1F) . In other cases, MART-1 mRNA-positive cells were associated with small clusters of macrophage-like cells that contained nuclei and nucleoli regarded as more typical of melanoma cells and also fine microdispersed melanin granules typical of melanogenic cells (Fig. 1G) . These cells were adjacent to typical melanophages ( Fig. 1H ) that had smaller, sometimes reniform, nuclei, inconspicuous nucleoli, and abundant coarse brown (aggregated) pigmented granules. Typical melanophages did not express MART-1 mRNA. Yet, other MART-1 mRNA-expressing cells, singly dispersed and scattered in the nodal parenchyma, had typical macrophage morphology with coarse brown pigmented granules (compound melanosomes) characteristic of melanophages ( Figs. 2A, B ). Immunohistochemistry on the corresponding SN/NSN tissue sections revealed that these MART-1 mRNA-expressing cells were negative for melanocytic markers, except in 2 cases in which positive signals for both HMB-45 and MART-1 were detected. In these 2 cases, singly dispersed and isolated immunoreactive cells that were HMB-45-positive and MART-1-positive, with nonatypical nuclei and coarse melanin granules, were readily identified as melanophages (Figs. 2C, D). Single isolated cells that were positive for MART-1 mRNA were detected in the corresponding RT in situ PCR slides. There was 1 example of nodal nevus in the examined lymph nodes, but the nevus cells were not detected by RT in situ PCR for MART-1 mRNA. Double staining for MART-1 mRNA by RT in situ PCR and for CD68 antigen by immunohistochemistry showed that 40% of the cells that contained MART-1 mRNA coexpressed MART-1 mRNA and CD68. Cells coexpressing MART-1 mRNA and CD68 were identified in areas in which there were abundant CD68-positive cells. Cells expressing MART-1 mRNA but not CD68 were colocalized in the same area as CD68-positive cells and cells that coexpressed MART-1 mRNA and CD68 (Figs. 2E, F) . As NBT/BCIP (blue/purple) and ACE (red) were used as chromogens, positive staining was clearly distinguishable from brown cytoplasmic melanin.
None of the 5 lymph nodes (SNs and NSNs) from patients with breast cancer showed positivity for MART-1 mRNA or MART-1 antigen (Figs. 2G, H) . None of these lymph nodes showed inclusions of melanocytic nevus cells.
DISCUSSION
Identification of melanoma cells in H&E-stained sections of SNs is usually straightforward when they form masses or clusters of tumor cells. However, early metastases may be seen as single melanoma cells, making their detection in H&E-stained sections more challenging, as such cells can show a considerable range of morphologic variation and are often amelanotic. Lightly pigmented or unpigmented melanoma cells may closely simulate sinus and other histiocytes that are often abundant in lymph nodes. Extended histopathologic search for small metastatic deposits by serial sectioning and immunohistochemistry reportedly detects occult melanoma cells in up to 32% of SNs. 39 Micrometastases may be missed if the wrong part of a node is examined or if tumor cells do not express melanoma-associated markers detectable by immunohistochemistry.
There are reports of patients with an intermediate prognosis who have an enhanced signal for mRNA for melanoma-associated genes detected by RT-PCR, in nodes that showed no evidence of melanoma cells on microscopic evaluation. 45 The RT in situ PCR technique is valuable in basic research and clinical science and permits detection of mRNA in specifically identifiable cells and tissues. In this study, we identified MART-1 mRNA-positive cells in SNs and NSNs in which a previous search for cells expressing MART-1 protein by immunohistochemistry was negative. Some of these cells are truly occult melanoma cells that, despite containing MART-1 mRNA, do not have detectable cytoplasmic MART-1 protein. Such "stealth" melanoma cells were also detected in microscopically tumor-free NSNs from patients with a tumor-positive SN. When a completion lymph node dissection is performed in patients with a positive SN, the tumor is detected in the NSN of 10% to 20% of patients. 21, 24, 43, 57 We showed that MART-1 mRNA-positive cells were also present in microscopically negative NSNs. The frequency of tumor-positive NSNs may increase when nodal tissues are evaluated by sensitive molecular analyses. 4 The biological significance of nodes found to contain tumor by special and extended evaluation remains unknown. The biological potential and significance of "stealth" melanoma cells also remains to be determined.
Human tumors express antigens recognized by autologous T lymphocytes. Tumor progression is often accompanied by alterations in the expression of such "differentiation" antigens, in some instances leading to tumor escape from immunosurveillance. Although MART-1 is detectable in most melanomas and is considered a suitable target for immunomodulation therapy, metastatic melanomas often show heterogeneous expression of MART-1. 15, 28, 33 Melanocyte-specific microphthalmiaassociated transcription factor regulates the expression of melanocyte-associated genes, and downregulation of microphthalmia-associated transcription factor results in the loss or reduced expression of melanoma-associated antigens in melanoma cells. 16, 36 Loss of melanoma-associated antigens may also be induced by soluble factors produced by melanoma cells, 37 including oncostatin M. 19 Thus, when attempting to detect micrometastases in SNs by molecular methods, attention should be paid to the possibility of downregulation of genes for tumor-associated antigen. The use of multiple melanoma markers can significantly improve the specificity of molecular testing. 65 Conversely, it may affect sensitivity, because alteration of melanomaassociated antigens has implications for tumor growth and metastasis, and these melanoma-associated antigens are downregulated in metastatic melanoma cells.
Alternative cellular sources for mRNA for melanoma-associated genes in lymph nodes include macrophages that have phagocytosed materials from melanoma cells. MART-1 mRNA was detected in macrophages (melanophages) containing intracellular granules of melanin. Colocalization of CD68 and RT in situ PCR-enhanced signal for MART-1 mRNA were found, further supporting the view that these cells are macrophages. Melanophage accumulation is typically observed at the primary site in the early stage of melanoma evolution. Single isolated melanophages and groups of melanophages forming small granulomas often mimic micrometastasis in regional lymph nodes. Large irregularly shaped intracellular granules of pigment, comprising aggregated melanosomes, are morphologic characteristics that help distinguish melanophages from melanoma cells in most instances in which the melanosomes are small, regular in size and shape, and diffusely dispersed. Electron microscopic examination has revealed that melanophages contain partially or fully melanized melanosomes that may be located within phagosomes. Melanosomes can also be found in dermal melanophages in postinflammatory hyperpigmentation 42, 63 or in tumor cells in cutaneous neoplasms other than melanoma, such as pigmented squamous cell carcinoma and pigmented basal cell carcinoma. 63 Melanosomes often exhibit immunoreactivity for HMB-45, 56 and HMB-45-positive melanophages have been demonstrated by immunoelectron microscopy. In contrast, MART-1 is not localized to melanosomes, but it is located in electron-lucent cytoplasmic vacuoles and vesicles in melanocytes. 64 Our study revealed that the MART-1 epitope is also detectable in melanophages, possibly indicating phagocytosed materials retained in their cytoplasm. However, we cannot entirely exclude the possibility that the highly sensitive molecular biology technique that we used may augment acquired nucleotides in the cytoplasm of macrophages that have phagocytosed melanoma cell components. MART-1-positive or HMB-45-positive melanophages may be difficult to differentiate from melanoma cells on light microscopy.
Melanoma-macrophage hybridization is another possible explanation for cells that express characteristics of both melanoma cells and macrophages. Until recently, the hypothesis that fusion of cancer cells and normal cells may facilitate metastasis has received limited attention. It has been suggested that cancer cells may spontaneously fuse with host cells to produce hybrids. 17, 18, 35, 49, 50 Evidence in support of cancer cell fusion with macrophages or other bone marrow-derived cells has been reported from studies of animal models of human cancer. 6, [9] [10] [11] 49, 52, 53, 59 Hybrid cells formed from macrophages and melanoma cells may possess the malignant potential of melanoma cells and the migratory phenotype of macrophages. Such hybrid cells contain coarse intracellular melanin granules of the type typically seen in melanophages. 53 In the tumor microenvironment, macrophages often constitute a major component of the tumor stroma. Macrophages are conventionally regarded as promoters of tumor progression 68 and are recruited to melanoma by expression of chemokines including CCL2 (monocyte chemoattractant protein-1). However, it is difficult to further track the underlying macrophages and demonstrate hybridization with tumor cells in human tissues. A recent study reported that epithelial cancers arise by transdifferentiation of bone marrow stem cells, a process that did not involve hybridization as these cells were diploid without evidence of fusion of donor and recipient cells. 23 Transdifferentiation of bone marrow stem cells to cancer cells may be another possible explanation of tumor dormancy and cancer cell metastasis.
In contrast, melanoma cells, particularly metastatic melanoma cells, may exhibit an aberrant immunophenotype and may express many of the known lysosomal and phagocytic markers, such as CD68, a1 antitrypsin, and a1 chymotrypsin, that are typical of macrophages. They also frequently show immunoreactivity with macrophage markers, including MAC387 and HAM56. 1, 20, 38, 51 Some melanoma cells express major histocompatibility complex class II molecules that are normally present on antigenpresenting cells and activated T cells. Metastatic melanoma cells may show macrophage-like phagocytic activities that involve cytoplasmic vesicles. 41 Macrophage-like properties have also been observed in gliomas, 29 which can preferentially express melanoma-associated antigens such as gp100, MART-1, tyrosinase, TRP-2, MAGE-A1, and MAGE-A3. 12, 54, 67 It remains unclear how melanoma cells develop aberrant macrophage-like immunophenotypes. The possibility that they are the result of melanoma-macrophage hybridization is clearly worthy of further consideration.
Another pitfall of the use of molecular biology techniques is that the "tumor-associated" genes used for detection of melanoma cells by RT-PCR are not absolutely specific to melanoma cells. These genes are mostly genes for melanocyte-lineage antigens that are also expressed by normal melanocytes and benign nevus cells. Nevus cells in lymph nodes represent a well-known potential diagnostic pitfall in the RT-PCR analysis. 61, 66 Histologically, nodal nevi appear as aggregates of nevus cells in the lymph node capsule and trabeculae and are a potential source of confusion with metastatic melanoma. Discrimination of benign nevocytes from metastatic melanoma requires close consideration of cytologic features of the cells that are negative or at the most faintly positive for HMB-45. 8 Although infrequent, benign inclusions in lymph nodes represent the presence of heterologous elements not normally found in lymph nodes. These include salivary inclusions in periparotid lymph nodes, thyroid inclusions in cervical lymph nodes, mammary gland inclusions in axillary lymph nodes, or endometrial glandular inclusions in abdominal and pelvic lymph nodes. 30, 60, 62 The occurrence of such inclusions provides an additional potential pitfall in the use of molecular biology to detect cancer metastases.
The prognostic significance of histology-negative RT-PCR-positive SNs remains debatable. There are no objective data to support or contradict complete lymph node dissection for histology-negative, molecular-positive SNs. A definitive answer must await completion of MSLT-2, a multicenter randomized trial in the United States, Europe, and Australia. 45 Although the clinical importance of the lymphatic system is well recognized, the actual molecular mechanisms involved remain poorly understood. As part of the elucidation of these mechanisms, improvements in the techniques and criteria involved in the detection of (early) lymph node metastasis of melanoma will be of considerable importance. These investigations will determine the clinical significance of "stealth" melanoma cells and other MART-1 mRNA-positive cells.
